Background

Treating in-stent restenosis still remains a great challenge for the interventional cardiologist. Our aim was to evaluate the efficacy of first-generation zotarolimus-eluting stents (ZES) (Endeavor, Medtronic) in the treatment of bare metal stent (BMS) restenosis.

Methods

Fifty-one consecutive patients with angiographically significant BMS restenosis were enrolled into the prospective, nonrandomised, single-centre clinical study. In-stent restenosis was treated with ZES. The primary end point was target lesion revascularization (TLR) at 1 year. Secondary end points included major adverse cardiac events (MACE) and angiographic in-stent late lumen loss (LL) by QCA at 1 year. Baseline characteristics included mean age of 61.65±8.4 years, 76.4% male, 13.7% diabetes. Reference vessel diameter before PCI (RVD) and lesion length were 2.81±0.53 and 15.05±9.38 mm, respectively; RVD after ZES implantation was 3.31±0.42 mm; acute gain, 1.84±0.68 mm. One hundred percent procedural success was achieved. Lifelong ASA and 12 months of clopidogrel were prescribed to all patients.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Successful collapse vessel treatment with a syringe for thrombus-aspiration after the guidewire-induced coronary artery perforation
2. Anterograde recanalisation of the radial artery followed by transradial angioplasty
3. Individualized cerebrospinal fluid drainage for preventing spinal cord ischemia in secondary TEVAR for type B dissection
4. One-year outcomes of everolimus-eluting and paclitaxel-eluting coronary stents in women: analysis from the Spirit IV Trial

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree